Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian for Prevention of Recurrent Cardiovascular Events After Acute Coronary Syndrome
2022-501418-69-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 45
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS), myocardial infarction (MI) and unstable angina comparing Milvexian arm with Placebo arm (2 arms). Primary endpoint: Time to first occurrence of MACE. Started Aug 2023; status: completed.
02
Drugs
milvexian
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)unstable angina
Beyond the preview
Go deeper on 2022-501418-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501418-69-00.